Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis

Archives of Medical Science

Volumn 12, Issue 4, 2016, Pages 828-843

  Cipriani, Paola ^a   Di Benedetto, Paola ^a   Dietrich, Hermann ^b   Ruscitti, Piero ^a   Liakouli, Vasiliki ^a   Carubbi, Francesco ^a   Pantano, Ilenia ^a   Berardicurti, Onorina ^a   Sgonc, Roswitha ^b   Giacomelli, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Animal model; Fibrosis

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYTOKINE; ENDOTHELIN 1; GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SCL 70 ANTIBODY; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ADULT; APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; BLOOD VESSEL OCCLUSION; CHICKEN; CONTROLLED STUDY; DISEASE DURATION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; LYMPHOCYTIC INFILTRATION; MALE; NONHUMAN; PATHOGENESIS; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

EID: 84977262197     PISSN: 17341922     EISSN: 18969151     Source Type: Journal    
DOI: 10.5114/aoms.2016.60970     Document Type: Article

References (41)

1. Trojanowska M. Role of PDGF in fbrotic diseases and systemic sclerosis. Rheumatology 2008; 47: v2-4.
2. Cipriani P, Marrelli A, Di Benedetto P, et al. Sclerodermia mesenchymal stem cells display a diferent phenotype from healthy controls; implications for regenerative medicine. Angiogenesis 2013; 16: 595-607.
3. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Gi-acomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011; 10: 590-4.
4. Wick G, Andersson L, Hala K, et al. Avian models with spontaneous autoimmune diseases. Adv Immunol 2006; 92: 71-117.
5. Beyer C, Schett G, Distler O, Distler JHW. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010; 62: 2831-44.
6. Sgonc R, Wick G. Pro-and anti-fbrotic Effects of TGF-beta in scleroderma. Rheumatology (Oxford) 2008; 475: v5-7.
7. Del Galdo F, Matucci-Cerinic M. The search for the perfect animal model discloses the importance of biological targets for the treatment of systemic sclerosis. Ann Rheum Dis 2014; 73: 635-6.
8. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classifcation criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism Collaborative Initiative. Arthritis Rheum 2013; 65: 2737-47.
9. van den Hoogen F, Khanna D, Fransen J, et al. 2013 clas-sifcation criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2013; 72: 1747-55.
10. Hunzelmann N, Genth E, Krieg T, et al. Registry of the German Network for Systemic Scleroderma. The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008; 47: 1185-92.
11. Waszczykowska A, Gos R, Waszczykowska E, Dziankow-ska-Bartkowiak B, Jurowski P. Prevalence of ocular manifestations in systemic sclerosis patients. Arch Med Sci 2013; 9: 1107-13.
12. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98: 785-92.
13. Sgonc R. The vascular perspective of systemic sclerosis: of chickens, mice and men. Int Arch Allergy Immunol 1999; 120: 169-76.
14. Kucia M, Jankowski K, Reca R, et al. CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol 2004; 35: 233-45.
15. Jo DY, Rafi S, Hamada T, Moore MA. Chemotaxis of primitive hematopoietic cells in response to stroma cell derived factor-1. J Clin Invest 2000; 105: 101-11.
16. Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where micro-environment influences their diferentiated phenotypes. Cancer Res 2006; 66: 9054-64.
17. Pablos JL, Amara A, Bouloc A, et al. Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol 1999; 155: 1577-86.
18. Cipriani P, Franca Milia A, Liakouli V, et al. Diferential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheumatism 2006; 54: 3022-33.
19. Seo J, Kim YO, Jo I. Diferential expression of stromal cell-derived factor 1 in human brain microvascular endothelial cells and pericytes involves histone modi-fcations. Biochem Biophys Res Commun 2009; 382: 519-24.
20. Middleton J, Neil S, Wintle J, et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 1997; 91: 385-95.
21. Abe R, Donnelly SC, Peng T et al. Peripheral blood fbro-cytes: diferentiation pathway and migration to wound sites. J Immunol 2001; 166: 7556-62.
22. Phillips RJ, Burdick MD, Hong K, et al. Circulating fbro-cytes trafc to the lungs in response to CXCL12 and mediate fbrosis. J Clin Invest 2004; 114: 438-46.
23. Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufcient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 109-16.
24. Distler O, Del Rosso A, Giacomelli R, et al. Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fngertip ulcers. Arthritis Res 2002; 4: R11.
25. Ciurzynski M, Bienias P, Irzyk K, et al. Heart diastolic dysfunction in patients with systemic sclerosis. Arch Med Sci 2014; 10: 445-54.
26. Mackiewicz Z, Sukura A, Povilenaité D, et al. Increased but imbalanced expression of VEGF and its receptors has no positive Effect on angiogenesis in systemic sclerosis skin. Clin Exp Rheumatol 2002; 20: 641-6.
27. Hagedorn M, Balke M, Schmidt A, et al. VEGF coordinates interaction of pericytes and endothelial cells during vasculogenesis and experimental angiogenesis. Dev Dyn 2004; 230: 23-33.
28. Dabek J, Głogowska-Ligus J, Bochenek A. Expression of angiogenesis-related genes in right atrial appendages from patients with advanced myocardial ischemia-preliminary results. Arch Med Sci 2013; 9: 540-3.
29. Leroy EC. Connective tissue synthesis by scleroderma skin fbroblasts in cell culture. J Exp Med 1972; 135: 1351-62.
30. Vancheeswaran R, Magoulas T, Efrat G, et al. Circulating endothelin-1 levels in systemic sclerosis subsets: a marker of fbrosis or vascular dysfunction? J Rheuma-tol 1994; 21: 1838-44.
31. Rajkumar VS, Sundberg C, Abraham DJ, Rubin K, Black CM. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 1999; 42: 930-41.
32. Prelog M, Scheidegger P, Peter S, Gershwin ME, Wick G, Sgonc R. Diminished TGF-beta2 production leads to increased expression of a profbrotic procollagen alpha 2 type I mRNA variant in embryonic fbroblasts of UCD-200 chickens, a model for systemic sclerosis. Arthritis Rheum 2005; 52: 1804-11.
33. Cambrey AD, Harrison NK, Dawes KE, et al. Increased levels of endothelin-1 in bronchoalveolar lavage fuid from patients with systemic sclerosis contribute to f-broblast mitogenic activity in vitro. Am J Respir Cell Mol Biol 1994; 11: 439-45.
34. Vancheeswaran R, Azam A, Black C, Dashwood MR. Localization of endothelin-1 and its binding sites in sclero-derma skin. J Rheumatol 1994; 21: 1268-76.
35. Kawaguchi Y, Suzuki K, Hara M, et al. Increased endo-thelin-1 production in fbroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53: 506-10.
36. Abraham DJ, Vancheeswaran R, Dashwood MR, et al. Increased levels of endothelin-1 and diferential endo-thelin type A and B receptor expression in scleroder-ma-associated fbrotic lung disease. Am J Pathol 1997; 151: 831-41.
37. Gay S, Jones Jr RE, Huang GQ, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sisoncogene expression in scleroderma. J Invest Dermatol 1989; 92: 301-3.
38. Klareskog L, Gustafsson R, Scheynius A, Hallgren R. Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis. Arthritis Rheum 1990; 33: 1534-41.
39. Cipriani P, Di Benedetto P, Ruscitti P, et al. Impaired endo-thelium-mesenchymal stem cells cross-talk in systemic sclerosis: a link between vascular and fbrotic features. Arthritis Res Ther 2014; 16: 442.
40. Daoussis D, Tsamandas AC, Liossis SN, et al. B-cell depletion therapy in patients with difuse systemic sclerosis associates with a signifcant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 2012; 14: R145.
41. Dziankowska-Bartkowiak B, Gerlicz-Kowalczuk Z, Wasz-czykowska E. Angiogenin and SDF-1alpha serum concentration in patients with systemic sclerosis in relation to clinical status. Arch Med Sci 2011; 7: 92-6.